Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
The $1.86 Trillion Gatekeeper
There is one company on Earth that can manufacture the chips powering every major AI model, and it just sent a clear message: the price of progress is going up. Taiwan Semiconductor Manufacturing Co. closed at $418.45 after touching an all-time high of $424.86 on May 28. A 15% price hike on its most advanced 3nm process is coming in the second half of 2026, and the buyers have no alternative.
🔹 The monopoly is absolute and widening. TSMC commands 72% of the global foundry market, but in the cutting-edge nodes below 7nm that power AI accelerators and next-generation smartphones, its share approaches 90%. The 3nm price increase is not a negotiation—it is a declaration. Every hyperscaler, every chip designer, and every government racing to build sovereign AI infrastructure must pass through TSMC's gates. The $56 billion capital expenditure budget for 2026, pushed to the top of the guided range, ensures that the competitive moat keeps deepening.
🔹 The financial engine is delivering historic torque. Earnings per share reached $12.02 on a trailing basis, reflecting the structural shift from a cyclical foundry to an AI infrastructure utility. The P/E ratio of 34.81 has sparked debate—some models suggest the stock is approximately 41% overvalued relative to intrinsic fair value. But scarcity commands a premium. Barclays raised its target to $470, and DA Davidson maintains a firm Buy rating. When the world's most critical manufacturing process has zero substitutes, traditional valuation metrics often fail to capture the strategic premium.
🔹 The macro tailwinds are accelerating. Global semiconductor revenue is projected to surge 37.5% in 2026, driven almost entirely by AI-related demand. The five largest cloud providers are spending a combined $690 billion this year, and a growing share of that flows directly into advanced packaging and 3nm wafers. TSMC's 52-week journey from $190.56 to $430.55 mirrors the AI supercycle itself—relentless, capital-intensive, and increasingly concentrated in a single geography.
🔹 Geopolitical risk is the counterweight that refuses to fade. Taiwan-China tensions remain the most significant binary risk in the global semiconductor supply chain. The US and European fab expansions—costly, complex, and years from matching Taiwan's output—are insurance policies, not replacements. The market has priced this risk before and rallied through it, but the sword of Damocles hangs permanently over the valuation. Every investor in TSMC is making a calculated bet that the world's dependence on its technology outweighs the geopolitical tail risk.
A 72% market share. A 15% price hike. A $470 analyst target that may prove conservative if the AI capex cycle extends through the decade. Taiwan Semiconductor is not a stock—it is the world's most critical manufacturing chokepoint. Are you paying the premium for the monopoly, or does the geopolitical risk keep your capital on the sidelines?
⚠️ Not financial advice.
$TSM #TradFi交易分享挑战
$971 Chip. $47 Cure.
The chasm between legacy and innovation has never been wider on American exchanges. As May 2026 closes, we are witnessing a brutal divergence: artificial intelligence infrastructure is minting trillion-dollar monarchs, while biotech pioneers scrape the bargain bin. The market is ruthlessly voting for the picks-and-shovels of the A.I. gold rush, and the story is told in the cold, hard prices of these five giants.
🔹 $MU — The Memory Monarch Takes the Crown
Micron crossed the $1 trillion market cap threshold for the first time this week, a historic moment that has analysts scrambling to catch up. The stock is now at $971.00 after smashing earnings estimates by over 40%. The secret? The entire 2026 supply of high-bandwidth memory is sold out. Analysts at MarketWise are now whispering about a $2,500 long-term target, arguing that this is no longer a cyclical stock but a structural A.I. utility.
🔹 #TSM — The Geopolitical Tollbooth
Taiwan Semiconductor sits at $418.45, up a staggering 117% year-over-year and hugging its all-time highs. Owning 72% of the global foundry market, TSMC just raised 3nm prices by 15% and cranked its CapEx to the top of its $56 billion range. You can't build A.I. without chips, and you can't build cutting-edge chips without TSMC. That is not a narrative; it is a geographical monopoly.
🔹 $JNJ — The Quiet Fortress
At $225.46, Johnson & Johnson is doing what defensive giants do: surviving. With a 2.18% dividend yield and a 12% year-to-date rise, it is the adult in the room. While facing the Stelara patent cliff, the MedTech and oncology pipelines are plugging the holes, making this a favorite for those seeking shelter from the tech sector's manic swings.
🔹 $MMM — The Legal Anchor
3M is stuck in the mud at $153.13, weighed down by the PFAS "forever chemicals" legacy in Australia. Despite operational improvements, the stock is down from its February high of $173. Analysts call it a "Hold" with an average target of $172.20, but until the legal fog clears, this is a yield play handcuffed by the past.
🔹 $MRNA — The Pipeline Roulette
Moderna has collapsed to $47.23, a painful fall for the pandemic darling. The COVID cash cow is gone, and the pivot to cancer vaccines and RSV combinations is an expensive bet. The short-term charts are weak. The long-term fate rests entirely on FDA clinical results. This is a high-risk biotech lottery ticket at a deep discount.
The gulf between A.I. hardware and struggling biotech is the defining feature of this market. Micron sells shovels; Moderna searches for miracles. Right now, the crowd is sprinting toward the hardware that builds the future while cautiously watching the science that heals it.
How are you positioning in this extreme divergence—doubling down on the A.I. infrastructure boom, or quietly accumulating the beaten-down innovators waiting for their clinical breakthrough?
⚠️ Not financial advice.